Efficacy of radioprotective agents in preventing small and large bowel radiation injury
Authors:
- 1 July 1995
- journal article
- research article
- Published by Wolters Kluwer Health in Diseases of the Colon & Rectum
- Vol. 38 (7) , 716-722
Abstract
PURPOSE: A variety of adjuvant treatments and cytoprotective agents have been proposed to lessen the toxicity of radiation therapy. The following study was designed to evaluate the benefit of six agents or combinations using anastomotic bursting strength as a measure of transmural radiation injury. METHODS: The 40-Gy study consisted of the following. Seventy-two male Sprague-Dawley rats were divided into eight equal groups: nonradiated control, radiated untreated control, and six radiated treated groups. The radioprotective treatments included ribose-cysteine (RibCys), WR-2721, glutamine, vitamin E, MgCl2/adenosine triphosphate, and RibCys/glutamine in combination. Radiated animals received 40 Gy to the abdomen. Two weeks after radiation, all animals underwent small bowel and colonic resection with primary anastomosis. Animals were sacrificed one week postoperatively, at which time anastomoses were evaluated and bursting strengths determined. The 70-Gy study consisted of the following. The same protocol was repeated for five groups of nine rats divided into nonradiated, radiated untreated, and three radiated treated groups receiving RibCys (8 mmol/kg), RibCys (20 mmol/kg), and WR-2721. All radiated animals received 70-Gy doses. RESULTS: In the 40-Gy group, there were 10 radiation-related deaths and 6 anastomotic leaks among 70 rats studied. None of the differences between groups were significant. Nonradiated control group small bowel and large bowel anastomotic bursting pressures were significantly elevated compared with all radiated groups. Compared with radiated controls, there were significant improvements in small bowel bursting strength in the RibCys, WR-2721, RibCys-glutamine, and vitamin E groups and significant improvement in colonic bursting strength in MgCl2/adenosine triphosphate, WR-2721, and RibCys groups. In the 70-Gy group, all nine nonradiated control rats survived. All eight untreated radiated control rats died, four of eight WR-2721 animals died (P=0.03), all RibCys (8 mmol/kg) animals died (P=0.03), and three of nine treated with RibCys (20 mmol/kg) survived (P=0.08). CONCLUSIONS: WR-2721 and RibCys gave consistent protection against large and small bowel radiation injury. The lower incidence of treatment-related toxicity and potentially equal or greater radioprotective effects may make RibCys more clinically useful than WR-2721.Keywords
This publication has 18 references indexed in Scilit:
- Protective effect of RibCys following high-dose irradiation of the rectosigmoidDiseases of the Colon & Rectum, 1993
- Use of radiation with or without WR-2721 in advanced rectal cancerCancer, 1992
- Mucosal protective effects of vitamin E and misoprostol during acute radiation-induced enteritis in ratsDigestive Diseases and Sciences, 1992
- Amino acids and their derivatives as radioprotective agentsAmino Acids, 1992
- Oral Glutamine Accelerates Healing of the Small Intestine and Improves Outcome After Whole Abdominal RadiationArchives of Surgery, 1990
- Efficacy of an absorbable mesh in keeping the small bowel out of the human pelvis following surgeryDiseases of the Colon & Rectum, 1988
- Low anterior anastomotic dehiscence following preoperative irradiation with 6000 radsDiseases of the Colon & Rectum, 1984
- Radiation Injury of the RectumAnnals of Surgery, 1981
- Operative management of radiation injuries of the intestinal tractThe American Journal of Surgery, 1979
- Surgical aspects of radiation injury to the intestineBritish Journal of Surgery, 1979